FiCAT CAR-T

FiCAT CAR-T refers to a next-generation chimeric antigen receptor (CAR) T-cell therapy produced using the proprietary FiCAT (Find and Cut-and-Transfer) gene-writing technology. Developed by Integra Therapeutics in collaboration with Universitat Pompeu Fabra, the FiCAT platform combines the precision of a CRISPR-Cas9 nuclease for genomic targeting with the high-capacity integration efficiency of an engineered PiggyBac transposase. This non-viral approach allows for the site-specific insertion of large, multigenic payloads into loci such as TRAC and B2M, potentially improving safety by avoiding random integration and reducing manufacturing costs by eliminating viral vectors. A primary candidate, FICAT-CAR-19/22, is a dual-targeted CAR-T cell therapy designed to treat B-cell malignancies and autoimmune diseases by simultaneously targeting CD19 and CD22. It incorporates a DHFR selection marker to facilitate the enrichment of engineered cells during expansion.

Other names

FiCAT-generated CAR-19/22 T cells